Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,828 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic value of combining cardiac myosin-binding protein C and N-terminal pro-B-type natriuretic peptide in patients without acute coronary syndrome treated at medical cardiac intensive care units.
Nishimura H, Ishii J, Takahashi H, Ishihara Y, Nakamura K, Kitagawa F, Sakaguchi E, Sasaki Y, Kawai H, Muramatsu T, Harada M, Yamada A, Tanizawa-Motoyama S, Naruse H, Sarai M, Yanase M, Ishii H, Watanabe E, Ozaki Y, Izawa H. Nishimura H, et al. Among authors: nakamura k. Heart Vessels. 2024 Dec 4. doi: 10.1007/s00380-024-02492-5. Online ahead of print. Heart Vessels. 2024. PMID: 39630269
Phase I/II trial of intracerebral transplantation of autologous bone marrow stem cells combined with recombinant peptide scaffold for patients with chronic intracerebral haemorrhage: a study protocol.
Kawabori M, Shichinohe H, Kahata K, Miura A, Maeda K, Ito YM, Mukaino M, Kogawa R, Nakamura K, Gotoh S, Kurisu K, Fujimura M. Kawabori M, et al. Among authors: nakamura k. BMJ Open. 2024 Dec 2;14(12):e083959. doi: 10.1136/bmjopen-2024-083959. BMJ Open. 2024. PMID: 39622566 Free article. Clinical Trial.
Incorporation of the central vein sign into the McDonald criteria.
Amin M, Nakamura K, Daboul L, O'Donnell C, Cao Q, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi PA, Cree BAC, Freeman L, Henry R, Longbrake EE, Oh J, Papinutto N, Pelletier D, Prčkovska V, Raza PC, Ramos M, Samudralwar R, Schindler M, Sotirchos ES, Sicotte N, Solomon AJ, Shinohara R, Reich DS, Sati P, Ontaneda D. Amin M, et al. Among authors: nakamura k. Mult Scler Relat Disord. 2024 Nov 25;93:106182. doi: 10.1016/j.msard.2024.106182. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 39622133
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. Marth C, et al. J Clin Oncol. 2024 Nov 26:JCO2401326. doi: 10.1200/JCO-24-01326. Online ahead of print. J Clin Oncol. 2024. PMID: 39591551
14,828 results
You have reached the last available page of results. Please see the User Guide for more information.